![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: McCoy Christopher
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.3, Iss.6, 2004-11, pp. : 625-637
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis
Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Should patients with severe sepsis receive drotrecogin alfa?
Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drotrecogin-alfa relatively cost effective in severe sepsis
Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drotrecogin alfa improves organ function in severe sepsis
Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. :